http://link.springer.com/article/10.1007/s10484-014-9267-4
Abstract
Depression and fatigue are common
symptoms of multiple sclerosis (MS) and are the primary determinants of
impaired quality of life in this demyelinating neurological disease.
Untreated depression is associated with suicidal ideation, impaired
cognitive function and poor adherence to immunomodulatory treatment. For
these reasons, systematic screening and management of depressive
symptoms and fatigue is recommended for all patients with MS. The
objective of this study was to evaluate the effectiveness of
neurofeedback in treating depression and fatigue in persons with MS. We
conducted a randomized trial with 24 MS patients with primary fatigue
and depression. Participants were randomized into two groups:
neurofeedback training group (16 sessions of NFB) or treatment as usual.
Participants were evaluated at 3 time points (baseline, end of the
treatment, and 2-month follow-up) using the Fatigue Severity Scale and
Depression subscale of the Hospital Anxiety and Depression Scale
as outcome measures. A repeated measures analysis of variance was used
to examine differences between the groups. NFB significantly reduced
symptoms of depression and fatigue in patients with MS patients,
compared to treatment as usual (p < .05), and these effects were maintained the 2-month follow-up (p < .05).
No comments:
Post a Comment